Pro-angiogenic miRNAs EBV-miR-BART10-5p and pro-metastatic hsa-miR-18a can be inhibited by their corresponding antagonists to slow tumour progression via downstream Spry3 pathway. Here, SPRY3 is linked to neoplasm.